Biocross presents a fast and cost-effective method for apolipoprotein E isotyping as an alternative to APOE genotyping for patient stratification in clinical trials at the 2015 Clinical Trials for Alzheimer’s disease (CTAD) meeting in November 2015.
Isoform E4 of human APOE, the gene that encodes apolipoprotein E (ApoE), is associated with increased risk of developing Alzheimer’s disease (AD). APOE genotyping is a source of much research interest and can be used both to stratify patients and to identify those at increased risk of AD. Several methods are used to distinguish APOE polymorphisms, including PCR and ELISA. However, these techniques require expensive reagents, involve multiple steps, and require informed consent for genetic analysis, limiting their use in routine clinical settings.
Biocross has developed a fast, cost-effective method for ApoE isotyping using specific monoclonal anti-ApoE4 antibodies that can be easily translated to a clinical laboratory setting using immunoturbidimetry assays. This method can be easily implemented and performed using any random-access high-throughput clinical chemistry platform, which are present in most clinical laboratories.
Presentation Details
Title: A fast and cost-effective method for apolipoprotein E isotyping as an alternative to APOE ε4 genotyping for patient stratification in clinical trials
Date/Time: 12 a.m. EST, Friday, November 6, 2016.
Location: Poster session 2 (P2-29), Gran Hotel Princesa Sofía, Barcelona, Spain.
